Shanghai, China - On December 25, 2017, the opening ceremony of Changsha Duzheng-Waters Joint Laboratory and the Evaluation Forum for Pharmaceutical Evaluation Technology was successfully held on December 23, 2017 in Changsha, Hunan Province.
President of Changsha Duzheng Biotechnology Co., Ltd., Professor Ouyang Dongsheng, Dr. Yu Peng, General Manager of Changsha Duzheng Biotech Co., Ltd., Dr. Li Xiaohui, Vice President of Changsha Duzheng Biotechnology Co., Ltd., General Manager of Waters Corporation in China Mr. Ran, Ms. Zhuang Shufan, General Manager of South China Region of Waters Corporation and Ms. Huang Jing, Marketing Director of Waters Corporation in China attended the ceremony and witnessed this historic moment together.
Leaders from both sides unveiled joint laboratories
In recent years, how to identify target drugs and biomarkers in complex matrices under the strict compliance environment has been promoted and supported by national policies on the evaluation of generic drug consistency, innovative drug research and development, clinical disease diagnosis and testing Become one of the hot spots in the market.At this time, the establishment of the joint laboratory aims to combine the strengths of both Duzhu and Waters in their respective fields of expertise to jointly promote the development and expansion of domestic compliance bioanalysis and clinical testing laboratories .
The joint lab is equipped with Waters' state-of-the-art total compliance solution to help drive the full scale up of DMPK research and clinical testing technologies
In his speech, Professor Ouyang Dongsheng, Chairman of Changsha Dusseldorf Biotech Co., Ltd., explained the background and significance of setting up a joint lab. "Given the current global pharmaceutical and clinical market data, China has tremendous growth opportunities and growth potential The establishment of Changsha TOSHIBA is our strategic decision to evaluate the consistency of the quality and efficacy of generic drugs at the critical moment of becoming a national strategy and a serious underdevelopment of research and development.We are all working hand in hand with Waters to jointly promote intelligence in information technology Laboratory construction to promote the research progress of pharmacokinetics. "Professor Ouyang Dongsheng said.
President of Changsha Duzheng Biotechnology Co., Ltd., Professor Ouyang Dongsheng delivered a speech
Mr. Yu Xiaran, general manager of Waters China, said in his speech: "Waters Corporation, as a leader in global analytical technology, has a rich and complete overall solution in the bioanalysis industry and laboratory informatization industry. Committed to clinical samples of separation and resolution more efficient, more stable and more compliance. The establishment of the joint laboratory will deepen the cooperation between the two sides in the pharmacokinetic studies, clinical testing research and personnel development made a breakthrough, for the Promote the development of Chinese drug research and clinical research play an important role.
Mr. Yu Xiaran, general manager of Waters China, made a speech
After the signing ceremony, Prof. Bing-Hua Su and Dr. Yanyan Yan of Changsha Duzheng Biotechnology Co., Ltd. made a speech entitled "Research on Clinical Statistics" and "Evaluation of BE and Consistency" at the Forum on Technological Innovation of Pharmaceutical Evaluation Industry held in the same period Lectures.Min Yong and Mr.Wang Fei, informatics experts from Waters Corporation, also carried out active discussions with the participants on topics such as computerized verification and application of pharmacokinetic studies in the optimization and evaluation of new drugs. discuss.
Pharmaceutical Evaluation Industry Technology Innovation Forum, all the experts to share on the wonderful report (from left to right are: Changsha are Biotechnology Co., Ltd. Professor Su Binghua, Dr. Song Yanyan, Waters Information Technology experts Jin Yong, DMPK Marketing Manager, Mr. Wang Fei )
After the conference, all the delegates visited the site and visited the 'Changsha Duzheng-Waters Joint Laboratory' and conducted in-depth exchanges with lab staff.
Joint lab visit
Since its establishment in 2016, Changsha Duzheng Biotech Co., Ltd. has been adhering to the core value of "innovation and truth-seeking" and is committed to becoming a high-tech biomedical enterprise integrating high-end technical services, professional training and product research and development. As one of the leaders in the bioanalysis industry and laboratory informationization industry, the company is committed to provide our clients with efficient, stable and compliant laboratory solution as a whole, with advanced and complete clinical sample analysis and testing Solution and a wealth of application cases.The overall solution of 'UPLC + Xevo TQD / TQ-S + UNIFI + Nugenesis' will help the overall improvement of pharmacokinetic research and clinical detection technology.